Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the Lexicon Pharmaceuticals' Second Quarter 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a brief -and-answer session. As a reminder, this call is being recorded today, August 6, 2025. I will now turn the call over to Lisa DiFrancisco, SVP Investor Relations and Corporate Communications for Lexicon. Please go ahead, Lisa. Thank you, Josh. Good morning and welcome to our Second Quarter 2025 Conference Call. Joining me today are Dr. Mike Exson, Lexicon's Chief Executive Officer and Director, Dr. Craig Granowitz, Senior Vice President and Chief Medical Officer, and Scott Chianti, Senior Vice President and Chief Financial Officer. This morning, Lexicon issued a press release announcing our financial results for the second quarter of 2025, which is available on our website at .lexpharma.com and through our SEC filing. A webcast of this call, along with a slide presentation, is also available on our website. During this call, we will review the information provided in the press release, provide a corporate update, then use the remainder of our time to answer your questions. Before we begin, let me remind you that we will be making forward-looking statements, including statements related to the safety, efficacy, clinical development, regulatory status, and therapeutic and commercial potential of -O-Vapidin, -5-1, Sotoconflozin, and our other drug programs, as well as our business generally. These statements may also include characterizations and projections relating to the clinical development, regulatory status, and market opportunity for our drug programs and the commercial performance of Impefa for heart failure. This call may also contain forward-looking ...